EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, PRTA, ARVN, SRPT, CRNX, and represent 42.37% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: SRPT (+$141M), CRNX (+$100M), CRSP (+$95M), MORF (+$77M), ADAP (+$43M), CLDX (+$27M), LENZ (+$27M), NKTX (+$22M), PCVX (+$21M), MDGL (+$20M).
- Started 16 new stock positions in CLDX, CRSP, KOD, PRME, KYTX, ALVR, RNA, ADAP, KROS, Alpine Immune Sciences. PCVX, NKTX, DYN, MDGL, ARQT, LENZ.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$435M), ARGX (-$115M), EWTX (-$41M), Graphite Bio (-$22M), SYRE (-$19M), RVMD, AVIR, Ngm Biopharmaceuticals, ALLK, TYRA.
- Sold out of its positions in SYRE, ALLK, ARGX, Graphite Bio, Mirati Therapeutics, Ngm Biopharmaceuticals, PHAT, RVMD, TYRA, NAMSW.
- EcoR1 Capital was a net buyer of stock by $47M.
- EcoR1 Capital has $4.0B in assets under management (AUM), dropping by 2.65%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 57 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Apellis Pharmaceuticals (APLS) | 16.9 | $668M | 11M | 58.78 |
|
|
Prothena Corp SHS (PRTA) | 7.3 | $287M | 12M | 24.77 |
|
|
Arvinas Ord (ARVN) | 7.0 | $278M | 6.7M | 41.28 |
|
|
Sarepta Therapeutics (SRPT) | 6.3 | $249M | +130% | 1.9M | 129.46 |
|
Crinetics Pharmaceuticals In (CRNX) | 4.9 | $195M | +106% | 4.2M | 46.81 |
|
Galapagos Nv Spon Adr (GLPG) | 4.7 | $185M | 5.8M | 32.20 |
|
|
Anaptysbio Inc Common (ANAB) | 4.3 | $169M | 7.5M | 22.52 |
|
|
Zymeworks Del (ZYME) | 3.6 | $141M | 13M | 10.52 |
|
|
Kura Oncology (KURA) | 3.5 | $139M | +12% | 6.5M | 21.33 |
|
Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.1 | $122M | 1.0M | 120.42 |
|
|
Xencor (XNCR) | 3.0 | $118M | 5.3M | 22.13 |
|
|
ACADIA Pharmaceuticals (ACAD) | 2.8 | $111M | 6.0M | 18.49 |
|
|
Tango Therapeutics (TNGX) | 2.7 | $106M | 13M | 7.94 |
|
|
Immunome (IMNM) | 2.4 | $96M | 3.9M | 24.68 |
|
|
Crispr Therapeutics Namen Akt (CRSP) | 2.4 | $95M | NEW | 1.4M | 68.16 |
|
Mersana Therapeutics (MRSN) | 2.2 | $87M | 19M | 4.48 |
|
|
Morphic Hldg (MORF) | 2.1 | $84M | +1028% | 2.4M | 35.20 |
|
Nuvation Bio Com Cl A (NUVB) | 1.8 | $70M | 19M | 3.64 |
|
|
Neurogene (NGNE) | 1.6 | $65M | 1.3M | 50.90 |
|
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.6 | $64M | 5.6M | 11.30 |
|
|
Oric Pharmaceuticals (ORIC) | 1.2 | $47M | 3.4M | 13.75 |
|
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 1.1 | $43M | NEW | 27M | 1.58 |
|
Tscan Therapeutics (TCRX) | 1.0 | $40M | 5.0M | 7.94 |
|
|
Voyager Therapeutics (VYGR) | 0.9 | $37M | 3.9M | 9.31 |
|
|
Third Harmonic Bio (THRD) | 0.8 | $30M | 3.2M | 9.44 |
|
|
Neumora Therapeutics (NMRA) | 0.7 | $29M | 2.1M | 13.75 |
|
|
Celldex Therapeutics Com New (CLDX) | 0.7 | $27M | NEW | 650k | 41.97 |
|
Iteos Therapeutics (ITOS) | 0.7 | $27M | +79% | 2.0M | 13.64 |
|
Lenz Therapeutics Com Added (LENZ) | 0.7 | $27M | NEW | 1.2M | 22.33 |
|
Atea Pharmaceuticals (AVIR) | 0.6 | $25M | -12% | 6.1M | 4.04 |
|
Alector (ALEC) | 0.6 | $24M | 4.1M | 6.02 |
|
|
Edgewise Therapeutics (EWTX) | 0.6 | $23M | -64% | 1.3M | 18.24 |
|
Nkarta (NKTX) | 0.5 | $22M | NEW | 2.0M | 10.81 |
|
Pharvaris N V (PHVS) | 0.5 | $21M | 900k | 23.11 |
|
|
Vaxcyte (PCVX) | 0.5 | $21M | NEW | 300k | 68.31 |
|
Madrigal Pharmaceuticals (MDGL) | 0.5 | $20M | NEW | 75k | 267.04 |
|
Avidity Biosciences Ord (RNA) | 0.5 | $19M | NEW | 758k | 25.52 |
|
Ovid Therapeutics (OVID) | 0.5 | $19M | 6.1M | 3.05 |
|
|
Verve Therapeutics (VERV) | 0.4 | $17M | 1.3M | 13.28 |
|
|
Keros Therapeutics (KROS) | 0.3 | $12M | NEW | 188k | 66.20 |
|
Dyne Therapeutics (DYN) | 0.3 | $12M | NEW | 427k | 28.39 |
|
Kyverna Therapeutics Com Added (KYTX) | 0.3 | $11M | NEW | 450k | 24.84 |
|
Gossamer Bio (GOSS) | 0.3 | $11M | 9.2M | 1.18 |
|
|
Kodiak Sciences (KOD) | 0.2 | $8.8M | NEW | 1.7M | 5.26 |
|
Allovir (ALVR) | 0.2 | $8.5M | NEW | 11M | 0.75 |
|
Generation Bio (GBIO) | 0.2 | $8.3M | 2.0M | 4.07 |
|
|
Atara Biotherapeutics (ATRA) | 0.2 | $7.1M | 10M | 0.69 |
|
|
Proqr Thrapeutics N V Shs Euro (PRQR) | 0.2 | $6.6M | -3% | 2.9M | 2.29 |
|
Aligos Therapeutics (ALGS) | 0.2 | $6.3M | 6.4M | 0.98 |
|
|
Arcutis Biotherapeutics (ARQT) | 0.1 | $5.0M | NEW | 500k | 9.91 |
|
Prime Medicine (PRME) | 0.1 | $4.9M | NEW | 700k | 7.00 |
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $3.5M | 963k | 3.64 |
|
|
Hookipa Pharma Inc equity (HOOK) | 0.1 | $3.3M | 4.6M | 0.71 |
|
|
Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.0M | 67k | 15.71 |
|
|
Pmv Pharmaceuticals (PMVP) | 0.0 | $964k | 567k | 1.70 |
|
|
Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $482k | 100k | 4.82 |
|
|
Alpine Immune Sciences | 0.0 | $40k | NEW | 1.0k | 39.64 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022
- EcoR1 Capital 2022 Q1 filed May 16, 2022
- EcoR1 Capital 2021 Q4 filed Feb. 14, 2022
- EcoR1 Capital 2021 Q3 restated filed Nov. 22, 2021
- EcoR1 Capital 2021 Q3 filed Nov. 15, 2021
- EcoR1 Capital 2021 Q2 filed Aug. 16, 2021
- EcoR1 Capital 2021 Q1 filed May 17, 2021
- EcoR1 Capital 2020 Q4 filed Feb. 16, 2021
- EcoR1 Capital 2020 Q3 filed Nov. 16, 2020